Taysha Gene Therapies
TSHA
TSHA
44 hedge funds and large institutions have $13.3M invested in Taysha Gene Therapies in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
44
Holders Change
-8
Holders Change %
-15.38%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
14
Closed
13
Calls
$2K
Puts
$4K
Net Calls
-$2K
Net Calls Change
-$106K
Top Buyers
1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$114K |
2 |
Millennium Management
New York
|
+$72.1K |
3 |
Bank of America
Charlotte,
North Carolina
|
+$69K |
4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$67.9K |
5 |
Morgan Stanley
New York
|
+$51.2K |
Top Sellers
1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1M |
2 |
ACM
Altium Capital Management
New York
|
-$811K |
3 |
BlackRock
New York
|
-$252K |
4 |
Renaissance Technologies
New York
|
-$215K |
5 |
UBS Group
Zurich,
Switzerland
|
-$158K |